São Paulo, June 24, 2025 – Eurofarma, the pharmaceutical company that invests the most in innovation in Brazil, announces its support for the Baby Minder project, an innovative medical device that uses computer vision and artificial intelligence to early detect signs of neurological conditions such as epilepsy, cerebral palsy, autism, and motor delays in babies aged 0 to 24 months.

Inspired by the design of a crib mobile, the device has been under development for over two years by WideLabs, the technology company responsible for Brazil's first sovereign AI, Amazônia 360º.

“By investing in projects still in the testing phase that harness technology at the service of the patient, such as Baby Minder, we are investing in the future of healthcare. We seek disruptive, sustainable innovations that can expand access to quality health. The medical-scientific appeal of this initiative is strong and generates a very positive expectation for accurate and early diagnoses,” comments Thiago Mônaco, Medical Manager at Eurofarma.

“Baby Minder is the result of years of research and development. We use artificial intelligence to create a tool that can transform the early detection of neurological conditions in babies, offering an accessible and effective solution,” says Rodrigo Malossi, Chief Technology Officer at WideLabs.

Currently, Baby Minder, with Eurofarma's support, is in its initial research phase at the Jundiaí University Hospital (SP) and the Jundiaí Faculty of Medicine, a national reference in neonatology, as well as in selected homes within the state of São Paulo to compose the study.

“The validation of Baby Minder in our hospital represents a significant advance in neonatal monitoring. The ability to early identify signs of neurological disorders allows us to intervene more effectively, improving the prognosis of our small patients,” highlights Dr. André Prado Grion, Clinical Director of the Jundiaí University Hospital.

With the progress of the studies, the expectation is that the device can reach thousands of families by 2026, especially in regions with limited access to specialized neurological exams.

Cannes Recognition 
The new project was featured at the Cannes Lions International Festival of Creativity, the world's most prestigious creativity and advertising festival. The initiative won a Silver Lion in the Innovation category, one of the festival's most competitive, recognizing pioneering solutions with the potential to transform markets and behaviors.

Digital Innovation as an Adjunct to Healthcare
In the search for a potentially scalable, affordable, and compliant solution with SUS protocols and the General Data Protection Law (LGPD), Eurofarma's support for the project reinforces its commitment to health, innovation, and social impact.

In the last year alone, Eurofarma invested over R$ 800 million in innovation, standing out as the pharmaceutical company that invests the most in Brazil in R&D and digital health. With over 750 scientists at Eurolab, its innovation center, the company also has an exclusive division focused on digital. Under the EurON brand umbrella are open innovation initiatives, market intelligence, digital health, intrapreneurship, and an investment fund focused exclusively on healthtechs.

Eurofarma is also proud to be the first Latin American pharmaceutical multinational to join the Digital Therapeutics Alliance (DTA), a non-profit entity dedicated to advancing the development of digital therapeutic solutions to support the transformation of the global health system.

Expansion of Central Nervous System Care
The new Baby Minder project relates to the central nervous system class, a segment where Eurofarma stands out for its broad portfolio and search for complementary solutions to conventional treatments.

Another innovative project connected to this thesis is the partnership with Protecting Brains & Saving Futures (PBSF), which monitors the brains of neonatal ICU patients to detect seizures in premature babies, with Eurofarma's sponsorship for equipment allocation in public hospitals, technical training for nursing teams, and remote medical support.

About Eurofarma
Founded in 1972, Eurofarma operates in the healthcare sector, producing and marketing products and services to improve people's quality of life. Focused on shared value generation, it covers key pharmaceutical segments such as prescription drugs, OTC and personal care, generics, hospital, oncology, and animal health, in addition to providing third-party manufacturing services. With broad coverage across therapeutic classes, the portfolio comprises over 4,000 SKUs, serving major medical specialties. A leader in medical prescriptions in Brazil, Eurofarma is present in 24 countries, with 100% coverage in Latin America and operations in the USA and Africa. It has 13,300 employees and 11 manufacturing plants, with a total production of 600 million units in 2024. In the same year, it invested over R$ 800 million in innovation projects and achieved a total net revenue of R$ 11 billion.

About Jundiaí University Hospital
Inaugurated in 2003, the Jundiaí University Hospital is a reference in maternal and child care for the Unified Health System (SUS) in the region. With excellence certification from the National Accreditation Organization (ONA), the hospital offers humanized and high-complexity care for a population estimated at over 900,000 inhabitants.

About WideLabs 
Founded in 2020, WideLabs is an award-winning Brazilian applied artificial intelligence company specialized in generative AI, computer vision, and predictive algorithms. Recognized for projects like Amazônia IA, the company works in partnership with global institutions and develops technological solutions focused on social impact and sovereign innovation.

Press Information
G&A Relações Públicas
e-mail: imprensaeurofarma@gaspar.com.br
Iza França - +55 11 97644-4496
Guilherme Gaspar -+55 11 98285-6000